Details for Patent: RE48960

Which drugs does patent RE48960 protect, and when does it expire?

Patent RE48960 protects AMONDYS 45 and is included in one NDA.

This patent has twenty-eight patent family members in thirteen countries.

Summary for Patent: RE48960

Title:	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Abstract:	An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
Inventor(s):	Stephen Donald Wilton, Sue Fletcher, Graham McClorey
Assignee:	University of Western Australia
Application Number:	US16/721,681
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent RE48960

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y		TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY INDUCING EXON-SKIPPING OF EXON 45
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y		TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING

Foreign Priority and PCT Information for Patent: RE48960

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	2004903474	Jun 28, 2004

International Family Members for US Patent RE48960

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	498685
Cyprus	1111447
Cyprus	1117475
Germany	602005026386